abs205.txt	purpose		stereotactic	body	radiation	therapy	(sbrt)	is	an	emerging	option	forlocalized	prostate	cancer		however		there	are	no	standard	dosimetric	guidelines	and	normal	tissue	tolerances	for	extreme	hypofractionation	are	not	well	defined	we	analyzed	dosimetric	correlations	with	patient-reported	urinary	and	bowelquality	of	life	(qol)	on	a	prospective	trial	methods	and	materials		patients	with	low-	or	intermediate-risk	prostate	cancerfrom	18	institutions	were	enrolled	on	a	phase	2	trial	from	2007	to	2012	andtreated	using	robotic	sbrt	to	38	gy	in	4	fractions	on	consecutive	days		noandrogen	deprivation	was	used		patients	received	simulation	with	foley	catheterfor	urethral	delineation		the	clinical	target	volume	was	prostate	(low-riskpatients)	or	prostate	plus	1	cm	of	proximal	seminal	vesicles	(intermediate-riskpatients)		multiple	dosimetric	measures	for	urethra		bladder		and	rectum	wereprospectively	recorded		qol	using	the	expanded	prostate	cancer	index	compositewas	assessed	before	and	after	treatment	at	protocol-specific	time	points		linearregression	was	used	to	assess	factors	associated	with	qol	at	1	month	and	2	years	results		a	total	of	259	patients	were	enrolled		qol	data	were	available	for	98%	96%		and	84%	at	baseline		1	month		and	2	years		respectively		median	age	was69	years		prior	transurethral	resection	of	the	prostate	and	clinical	targetvolume	size	were	associated	with	2-year	urinary	incontinence		there	was	a	trendtoward	worse	2-year	obstruction/irritation	in	older	patients	on	multivariableanalysis		bladder	and	urethral	doses	were	not	associated	with	either	1-month	or2-year	urinary	qol		in	contrast		rectum	maximum	dose	was	associated	with	both1-month	and	2-year	bowel	qol		at	2	years		the	proportion	with	moderate	or	bigoverall	bowel	problems	(as	defined	by	expanded	prostate	cancer	indexcomposite-26)	was	significantly	higher	in	patients	with	rectum	maximum	dosegreater	than	versus	less	than	the	median	37	4	gy	(11%	vs	2%		fisher's	exact	testp	=		008)	conclusions		these	results	provide	novel	data	that	contribute	to	a	betterunderstanding	of	patient	and	dosimetric	factors	associated	with	adverse	qoleffects	from	prostate	sbrt	
